Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2008

View Archived Issues

PRX-03140 improves ADAS-Cog scores in Alzheimer's disease patients

Abbott's A-887755 under development for passive immunotherapy in Alzheimer's disease

BMS-708163, a novel gamma-secretase inhibitor, has good pharmacological profile in animals, humans

Bristol-Myers Squibb describes creation of intranasal CGRP antagonist for migraine

Genzyme reviews quarterly highlights

The Medicines Company acquires Curacyte Discovery

InteKrin completes first close of series C venture financing for USD 18.25 million

Roche profiles H1 developments

AGS-004 immunogenic in HIV patients treated with antiretroviral therapy

Pfizer reports identification of a new series of noradrenaline reuptake inhibitors

PET probe developed for imaging of immune disorders

Ariad initiates phase II clinical trial of deforolimus in advanced endometrial cancer

Cara reports positive results from phase Ia clinical trial of CR-845 for acute and chronic pain

Tolerx initiates phase III DEFEND clinical trial of otelixizumab in type 1 diabetes

Novel agents for treatment of pain, migraine, etc., patented

Inhibitex completes phase I clinical trial and initiates multiple ascending dose trial of FV-100

Achillion receives private placement financing of approximately USD 41.5 million

Recent patents reveal discovery of compounds for Alzheimer's, Parkinson's, etc.

Discovery to submit complete response to Surfaxin approvable letter by September 2008

Novel antiinfective agents disclosed in recent patents

NIAID commits USD 7.5 million of continued funding to Alnylam to develop RNAi antiviral

Biovest joins Joint U.S.-Norway Cancer Research Program

Alnylam eyes IND filing for ALN-VSP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...